Similar articles for PMID: 30194214

Year	Number of Results
2003	1
2006	1
2009	1
2010	2
2011	5
2012	8
2013	11
2014	9
2015	27
2016	20
2017	24
2018	41
2019	39
2020	21
2021	14
2022	16
2023	4
2024	0

1

Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.

Jordan F, Grundmann N, Schenkirsch G, Märkl B, Messmann H, Anthuber M, Schmid C, Trepel M. Jordan F, et al. Anticancer Res. 2018 Sep;38(9):5539-5546. doi: 10.21873/anticanres.12889. Anticancer Res. 2018. PMID: 30194214

2

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

Huemer F, Thaler J, Piringer G, Hackl H, Pleyer L, Hufnagl C, Weiss L, Greil R. Huemer F, et al. BMC Cancer. 2018 Jan 3;18(1):11. doi: 10.1186/s12885-017-3955-4. BMC Cancer. 2018. PMID: 29298682 Free PMC article.

3

Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.

Aljehani MA, Morgan JW, Guthrie LA, Jabo B, Ramadan M, Bahjri K, Lum SS, Selleck M, Reeves ME, Garberoglio C, Senthil M. Aljehani MA, et al. JAMA Surg. 2018 Jan 1;153(1):60-67. doi: 10.1001/jamasurg.2017.3466. JAMA Surg. 2018. PMID: 28975237 Free PMC article.

4

Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.

Snyder M, Bottiglieri S, Almhanna K. Snyder M, et al. Rev Recent Clin Trials. 2018;13(2):139-149. doi: 10.2174/1574887113666180328104109. Rev Recent Clin Trials. 2018. PMID: 29595113

5

Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.

Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, Wang JY. Tsai HL, et al. Int J Clin Exp Pathol. 2015 Feb 1;8(2):1900-10. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 25973082 Free PMC article.

6

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Hegewisch-Becker S, et al. Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361971 Clinical Trial.

7

Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.

Roohullah A, Wong HL, Sjoquist KM, Gibbs P, Field K, Tran B, Shapiro J, Mckendrick J, Yip D, Nott L, Gebski V, Ng W, Chua W, Price T, Tebbutt N, Chantrill L. Roohullah A, et al. World J Gastroenterol. 2015 May 7;21(17):5352-8. doi: 10.3748/wjg.v21.i17.5352. World J Gastroenterol. 2015. PMID: 25954110 Free PMC article.

8

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. Holch JW, et al. Eur J Cancer. 2017 Jan;70:87-98. doi: 10.1016/j.ejca.2016.10.007. Epub 2016 Nov 29. Eur J Cancer. 2017. PMID: 27907852

9

Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.

Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Antonuzzo L, et al. World J Gastroenterol. 2015 Jun 21;21(23):7281-8. doi: 10.3748/wjg.v21.i23.7281. World J Gastroenterol. 2015. PMID: 26109816 Free PMC article. Clinical Trial.

10

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Venook AP, et al. JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105. JAMA. 2017. PMID: 28632865 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

213 results

Results by year